GlassScriptPhysician profile
Nathaniel Methot
NPI 1225422140
$1,098.86
in general payments reported to CMS, 2019-2025
22 companies · $334 in 2025
The $334 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.49 · 2022: $34.88 · 2023: $484 · 2024: $230 · 2025: $334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,047.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,047.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $132.41 | 2023-2025 | |
| Dermavant Sciences, INC. | $117.50 | 2023 | Vtama |
| Novo Nordisk INC | $114.66 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Gilead Sciences, INC. | $113.95 | 2022-2025 | Epclusa |
| Lilly USA, LLC | $86.49 | 2022-2024 | Mounjaro |
| Corcept Therapeutics | $75.75 | 2024-2025 | Korlym |
| Vanda Pharmaceuticals INC. | $60.04 | 2024-2025 | Fanapt, Hetlioz |
| Bayer Healthcare Pharmaceuticals INC. | $48.78 | 2024-2025 | |
| Organon LLC | $42.91 | 2023 | Nexplanon, Nuvaring |
| Exact Sciences Corporation | $39.50 | 2023 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $36.33 | 2024-2025 | Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $35.86 | 2023-2024 | Entyvio |
| Amgen INC. | $31.15 | 2023-2025 | Otezla, Repatha, Prolia |
| Aimmune Therapeutics, INC. | $28.82 | 2025 | Vowst |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.35 | 2023 | Xifaxan |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $18.92 | 2024 | |
| Madrigal Pharmaceuticals | $18.78 | 2025 | Rezdiffra |
| Astellas Pharma US INC | $17.94 | 2024 | Veozah |
| Merck Sharp & Dohme LLC | $16.49 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $15.63 | 2023 | Rexulti |
| Pfizer INC. | $13.60 | 2025 | |
| Idorsia Pharmaceuticals US INC | $13.00 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathaniel Methot listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.